Metabolomics in Neurodegeneration

Migration, Crosslink

📖

Metabolomics in Neurodegeneration

active

wiki page Created: 2026-04-02T07:19:59 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-mechanisms-metabolomics-neurodegene

📖 Wiki Page

mechanism875 wordssynced 2026-04-02

Metabolomics in Neurodegeneration

Metabolomics is the large-scale study of small molecule metabolites within biological systems. In neurodegeneration research, metabolomics provides a functional readout of cellular metabolism and has emerged as a powerful approach for discovering [biomarkers](/mechanisms/biomarkers-neurodegeneration), understanding disease mechanisms, and identifying therapeutic targets.

Overview

flowchart TD Metabolomics_in_Neurodegenerat["Metabolomics in Neurodegeneration"] Metabolomics_in_Neurodegenerat["large-scale"] Metabolomics_in_Neurodegenerat -->|"related to"| Metabolomics_in_Neurodegenerat style Metabolomics_in_Neurodegenerat fill:#81c784,stroke:#333,color:#000 Metabolomics_in_Neurodegenerat["study"] Metabolomics_in_Neurodegenerat -->|"related to"| Metabolomics_in_Neurodegenerat style Metabolomics_in_Neurodegenerat fill:#81c784,stroke:#333,color:#000 Metabolomics_in_Neurodegenerat["small"] Metabolomics_in_Neurodegenerat -->|"related to"| Metabolomics_in_Neurodegenerat style Metabolomics_in_Neurodegenerat fill:#81c784,stroke:#333,color:#000 style Metabolomics_in_Neurodegenerat fill:#4fc3f7,stroke:#333,color:#000

...

Metabolomics in Neurodegeneration

Metabolomics is the large-scale study of small molecule metabolites within biological systems. In neurodegeneration research, metabolomics provides a functional readout of cellular metabolism and has emerged as a powerful approach for discovering [biomarkers](/mechanisms/biomarkers-neurodegeneration), understanding disease mechanisms, and identifying therapeutic targets.

Overview

Mermaid diagram (expand to render)

Metabolomics complements [genomics](/mechanisms/genetics), [proteomics](/mechanisms/proteomics-overview), and [transcriptomics](/mechanisms/transcriptomics-neurodegeneration) by measuring the end products of cellular processes. The metabolome reflects the combined influence of genetic variation, environmental factors, and disease pathology, making it particularly valuable for understanding complex [neurodegenerative disorders](/diseases/alzheimers-disease) like [Alzheimer's disease](/diseases/alzheimers-disease) (AD) and [Parkinson's disease](/diseases/parkinsons-disease) (PD)[@patti2012].

Metabolic Biomarkers in Neurodegeneration

Alzheimer's Disease

Multiple metabolite alterations have been identified in AD:

[Sphingolipids](/mechanisms/sphingolipid-metabolism-alzheimers): Ceramide and sulfatide reductions correlate with cognitive decline[@cheng2023]
[Phosphatidylcholines](/mechanisms/lipid-metabolism-neurodegeneration): Decreased in AD plasma and CSF[@whiley2021]
[Amino acids](/mechanisms/amino-acid-metabolism-neurodegeneration): Altered glutamate, GABA, and tryptophan metabolism[@gonzlezdomnguez2015]
[Organic acids](/mechanisms/organic-acid-metabolism-neurodegeneration): Elevated lactate and decreased alpha-ketoglutarate in AD brain[@mahajan2022]

Parkinson's Disease

PD-specific metabolic changes include:

[Uric acid](/mechanisms/urate-neuroprotection-parkinsons): Lower levels associated with increased PD risk[@weisskopf2007]
[Coenzyme Q10](/mechanisms/coq10-neurodegeneration): Decreased in PD patients and linked to [mitochondrial dysfunction](/mechanisms/mitochondrial-dysfunction)[@shults2002]
[Glutathione](/mechanisms/glutathione-neurodegeneration): Reduced in [substantia nigra](/brain-regions/substantia-nigra) of PD patients[@sian1994]

Metabolome-Wide Association Studies (MWAS)

MWAS examine the relationship between the metabolome and disease phenotypes. Key findings include:

Identification of novel [biomarker panels](/biomarkers/alzheimers-disease-biomarkers) for AD diagnosis[@arnold2020]
Detection of [metabolic signatures](/mechanisms/disease-metabolic-signatures) that predict disease progression[@tynkkynen2018]
Integration with [genetic data](/mechanisms/genetics) to identify causal metabolites[@shin2014]

Analytical Methods

Nuclear Magnetic Resonance (NMR)

[NMR spectroscopy](/technologies/nmr-spectroscopy-neurodegeneration) offers several advantages for metabolomics:

Non-destructive analysis
High reproducibility
Minimal sample preparation
Quantitative capability[@emwas2015]

Mass Spectrometry (MS)

[Mass spectrometry](/technologies/mass-spectrometry-neurodegeneration)-based approaches provide:

High sensitivity
Broad metabolite coverage
Targeted and untargeted analysis
Integration with chromatography (GC-MS, LC-MS)[@dettmer2007]

Key Metabolites in Neurodegeneration

| Metabolite | Disease | Direction | Clinical Relevance |
|------------|---------|-----------|-------------------|
| Sphingomyelin | AD | Decreased | Diagnostic biomarker |
| Phosphatidylserine | AD | Decreased | Disease progression |
| Uric acid | PD | Decreased | Risk factor |
| CoQ10 | PD | Decreased | Therapeutic target |
| Lactate | AD/PD | Increased | Energy metabolism |
| Glutathione | PD | Decreased | Oxidative stress |

Blood and CSF Metabolite Profiles

Cerebrospinal Fluid (CSF)

CSF metabolomics provides direct insight into [brain metabolism](/mechanisms/brain-energy-metabolism):

Reduced [glucose metabolism](/mechanisms/glucose-metabolism-alzheimers) in AD[@lin2006]
Altered [neurotransmitter metabolites](/mechanisms/neurotransmitter-changes-neurodegeneration)[@zheng2021]
Elevated [inflammatory-related metabolites](/mechanisms/neuroinflammation)[@mapstone2014]

Blood-Based Metabolomics

[Peripheral biomarkers](/biomarkers/blood-based-neurodegeneration-biomarkers) offer practical advantages:

Less invasive collection
Suitable for longitudinal studies
Emerging multi-analyte panels[@ryu2020]

Integration with Other Omics

Metabolomics data integrates with other [omics](/mechanisms/multi-omics-neurodegeneration) layers:

[Genomics](/mechanisms/genomics-neurodegeneration): Genetic variants affecting metabolite levels[@suhre2011]
[Transcriptomics](/mechanisms/transcriptomics-neurodegeneration): Gene expression changes reflected in metabolites[@krumsiek2011]
[Proteomics](/mechanisms/proteomics-overview): Enzyme activity affecting metabolic pathways[@patti2012a]

Therapeutic Implications

[Metabolomic approaches](/therapeutics/metabolomics-based-therapeutics) support therapeutic development:

Target identification: Metabolic vulnerabilities in neurodegeneration

Biomarker development: Patient stratification and treatment response

Drug metabolism: Understanding pharmacokinetics in CNS diseases[@kaddurahdaouk2008]

Cross-Links

[Biomarkers](/mechanisms/biomarkers-neurodegeneration)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
[Oxidative Stress](/mechanisms/oxidative-stress)

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Recent Research Updates (2024-2026)

[Chen et al. 2024: Spatial multimodal analysis of transcriptomes and metabolomes in tissues — metabolomics in neurodegenerative disease (2024)](https://pubmed.ncbi.nlm.nih.gov/37667091/)

References

[Kaddurah-Daouk R, Weinshilboum RM, Pharmacometabolomics: implications for clinical pharmacology (2014)](https://pubmed.ncbi.nlm.nih.gov/24193171/)

[Patti GJ, Yanes O, Siuzdak G, Metabolomics: the apogee of the omics trilogy (2012)](https://pubmed.ncbi.nlm.nih.gov/22475752/)

[Cheng H, Wang M, Li JL, et al, Sphingolipid metabolism in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37648975/)

[Whiley L, Langford J, Zetterberg H, et al, Metabolomic biomarkers for Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33395168/)

[González-Domínguez R, García-Barrera T, Gómez-Ariza JL, Metabolomic approaches to investigate metabolic alterations in Alzheimer's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25916546/)

[Mahajan UV, Varma VR, Huang J, et al, Metabolomic signatures of Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35245482/)

[Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A, Plasma urate and risk of Parkinson's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17468177/)

[Shults CW, Oakes D, Kieburtz K, et al, Effects of coenzyme Q10 in early Parkinson disease (2002)](https://pubmed.ncbi.nlm.nih.gov/12163726/)

[Sian J, Dexter DT, Lees AJ, et al, Glutathione depletion in the substantia nigra (1994)](https://pubmed.ncbi.nlm.nih.gov/7978540/)

[Arnold M, Nho K, Kueider-Paisley A, et al, Metabolomics for Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32830206/)

[Tynkkynen J, Chouraki V, van der Lee SJ, et al, Metabolic profiling of incident diabetes (2018)](https://pubmed.ncbi.nlm.nih.gov/30104762/)

[Shin SY, Fauman EB, Petersen AK, et al, An atlas of genetic influences on human blood metabolites (2014)](https://pubmed.ncbi.nlm.nih.gov/24816252/)

[Emwas AH, The strengths and weaknesses of NMR spectroscopy and mass spectrometry (2015)](https://pubmed.ncbi.nlm.nih.gov/26030424/)

[Dettmer K, Aronov PA, Hammock BD, Mass spectrometry-based metabolomics (2007)](https://pubmed.ncbi.nlm.nih.gov/17982442/)

[Lin MT, Beal MF, Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases (2006)](https://pubmed.ncbi.nlm.nih.gov/17005044/)

[Zheng H, Zhang C, Luo W, et al, CSF neurotransmitter metabolites in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34365849/)

[Mapstone M, Cheema AK, Fiandaca MS, et al, Plasma phospholipids identify antecedent memory impairment (2014)](https://pubmed.ncbi.nlm.nih.gov/25100165/)

[Ryu do Y, Song SH, Lee KA, et al, Blood metabolomics for biomarker discovery in Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32868679/)

[Suhre K, Shin SY, Petersen AK, et al, Human metabolic individuality in biomedical and pharmaceutical research (2011)](https://pubmed.ncbi.nlm.nih.gov/21849506/)

[Krumsiek J, Suhre K, Illig T, Adamski J, Theis FJ, Bayesian multivariate analysis of metabolomics data (2011)](https://pubmed.ncbi.nlm.nih.gov/21677137/)

[Patti GJ, Tautenhahn R, Rinehart D, et al, A view from on high: NIST metabolomics standards (2012)](https://pubmed.ncbi.nlm.nih.gov/23179867/)

[Kaddurah-Daouk R, Kristal BS, Weinshilboum RM, Metabolomics: a global biochemical approach to drug response and disease (2008)](https://pubmed.ncbi.nlm.nih.gov/18319048/)

📖 View canonical wiki page →

Related Entities

mechanisms-metabolomics-neurodegeneration

▸Metadataorigin_type: v1_polymorphic_backfill

slug	mechanisms-metabolomics-neurodegeneration
kg_node_id	None
entity_type	mechanism
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-f71c1d339325
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'mechanisms-metabolomics-neurodegeneration'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

552

Outgoing

711

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Metabolomics in Neurodegeneration

Metabolomics in Neurodegeneration

Overview

Metabolomics in Neurodegeneration

Overview

Metabolic Biomarkers in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

Metabolome-Wide Association Studies (MWAS)

Analytical Methods

Nuclear Magnetic Resonance (NMR)

Mass Spectrometry (MS)

Key Metabolites in Neurodegeneration

Blood and CSF Metabolite Profiles

Cerebrospinal Fluid (CSF)

Blood-Based Metabolomics

Integration with Other Omics

Therapeutic Implications

Cross-Links

See Also

External Links

Recent Research Updates (2024-2026)

References

💬 Discussion